02.07.2018

MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy

MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced MagForce USA has enrolled the first patient in its pivotal clinical evaluation with the ...

 

14.06.2018

MagForce AG Co-Sponsors the University Hospital of Münster’s Annual Brain Cancer Patient Event

Berlin, Germany and Nevada, USA, June 14, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is delighted to announce that the Company will again co-sponsor an event for brain cancer patients and ...

 

12.06.2018

MagForce AG Announces Collaboration Agreement for NanoTherm® Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland

Berlin, Germany and Nevada, USA, June 12, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that it has entered into a collaboration agreement with Independent Public Clinical ...

 

04.06.2018

MagForce AG to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)

Berlin, Germany and Nevada, USA, June 4, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a scientific lunch symposium titled “Local Therapies for ...

 

03.05.2018

MagForce AG publishes Directors' Dealings

download PDF